Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma

The fibroblast growth factor receptor 4 (FGFR4) is overexpressed in rhabdomyosarcoma (RMS) and represents a promising target for treatments based on specific and efficient antibodies. Despite progress, there is an urgent need for targeted treatment options to improve survival rates, and to limit lon...

Full description

Bibliographic Details
Main Authors: Nagjie Alijaj, Sandrine Moutel, Zelia L. Gouveia, Maxim Gray, Maurizio Roveri, Dzhangar Dzhumashev, Florian Weber, Gianmarco Meier, Paola Luciani, Jochen K. Rössler, Beat W. Schäfer, Franck Perez, Michele Bernasconi
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
rhabdomyosarcoma
FGFR4
single-domain antibody
targeted liposomes
CAR T cells
Online Access:https://www.mdpi.com/2072-6694/12/11/3313

Internet

https://www.mdpi.com/2072-6694/12/11/3313

Similar Items